enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. WeightWatchers stock soars, but its cheap Wegovy ... - AOL

   www.aol.com/finance/weightwatchers-rallies-170...

   WW International (i.e. WeightWatchers) stock jumped nearly 40% Wednesday following the news, and the stock climbed an additional 23% Thursday to close at $1.96. WW is up 172% from last week.

3. GLP-1 questions emerge for 2025 [Video] - AOL

   www.aol.com/finance/glp-1-questions-emerge-2025...

   That includes GLP-1s, of course. Follow Anjalee on social media platforms X (Twitter), LinkedIn Bluesky @AnjKhem . Click here for in-depth analysis of the latest health industry news and events ...

4. FDA finalizes decision to end Lilly's GLP-1 shortage ... - AOL

   www.aol.com/finance/fda-finalizes-decision-end...

   The news still crushed Hims stock Thursday afternoon. Shares traded down nearly 10% at $25.81 per share. Hims shares slid further on Friday before the bell by 4%.

5. GLP-1 pills are coming, and they could revolutionize weight ...

   www.aol.com/news/glp-1-pills-coming-could...

   At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, with the most advanced now in the third and final stage of testing.

6. Wall Street is still jittery on GLP-1s [Video] - AOL

   www.aol.com/finance/wall-street-still-jittery...

   Wall Street has taken medical devices, as well as other sectors, on a roller-coaster ride in the past year in anticipation of an outsized impact from GLP-1s, which has yet to materialize.

7. Allurion launches compounded GLP-1 program as FDA aims ... - AOL

   www.aol.com/finance/allurion-launches-compounded...

   The news may help, but the plan is independent of it." The company's stock fell on the news of the announcement Monday, trading down nearly 3% to $0.41 per share. StockStory aims to help ...

8. PepsiCo CEO: GLP-1 drugs are 'not impacting us' [Video] - AOL

   www.aol.com/finance/pepsico-ceo-glp-1-drugs...

   The demand for GLP-1 drugs has skyrocketed. In 2023, Novo Nordisk’s diabetes and weight-loss drugs — Ozempic, Rybelsus, and Wegovy — brought in $21 billion in sales, an 89% increase over the ...

9. JPM's annual healthcare conference: Here's what's next ... - AOL

   www.aol.com/finance/jpms-annual-healthcare...

   Several big pharma companies are rushing into the GLP-1 obesity space, which currently has two market leaders. How they plan to take some of that market share will be the story of the drug class ...